The goal of the Phase I part of this clinical research study is to find the highest safe dose
of bendamustine that can be given to patients with acute myelogenous leukemia (AML), Acute
lymphoblastic leukemia (ALL), Chronic myelogenous (or myeloid) leukemia (CML) in blastic
phase, Chronic Myelomonocytic Leukemia (CMML), and myelodysplastic syndromes (MDS).
The goal of the Phase II part of this clinical research study is to learn if bendamustine can
help to control AML, ALL and MDS. The safety of this drug will continue to be studied.